Unicycive Therapeutics Inc. (UNCY)
Unicycive Therapeutics Announces Receipt of Complete Response Letter for Oxylanthanum Carbonate for the Treatment of Hyperphosphatemia in Patients with Chronic Kidney Disease on Dialysis
Unicycive Therapeutics Announces Receipt of Complete Response Letter for Oxylanthanum Carbonate for the Treatment of Hyperphosphatemia in Patients with Chronic Kidney Disease on Dialysis
Celcuity Reports Clinical Data from Two Early Phase Studies of Gedatolisib
A New Press Release from Oncolytics Biotech, Inc
Moderna - Moderna Announces Positive Phase 3 Results for Seasonal Influenza Vaccine
Rocket Pharmaceuticals Announces FDA IND Clearance of RP-A701 for the Treatment of BAG3-associated Dilated Cardiomyopathy
AN2 Therapeutics Reports Key Insights from 200-Patient Observational Study in Acute Melioidosis, Laying Groundwork for Phase 2 Proof-of-Concept Trial of Epetraborole
Cassava Presents Promising Preclinical Simufilam Data at TSC Alliance Meeting
New Form 8-K - ARVINAS, INC. Filed: 2025-06-30 AccNo: 0001655759-25-000128 Size: 157 KB Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers Item 5.07: Submission of Matters to a Vote of Security Holders
Iterum Names Christine Coyne as Chief Commercial Officer to LeadORLYNVAH™ Launch and Commercial Growth
Avadel Pharmaceuticals Announces Unanimous Appeals Court Decision Upholding FDA Approval of LUMRYZ in Narcolepsy in Administrative Procedure Act Litigation
Oncolytics Biotech® Appoints Former Ambrx Executive as Chief Business Officer to Drive Business Development Strategy
Tonix Pharmaceuticals Announces Inclusion in the Russell 3000® and Russell 2000® Indexes
Bausch + Lomb Will Release Second-Quarter 2025 Financial Results on July 30 and Hold Investor Day on Nov. 13